Category: InSightec LtdSyndicate content

InSightec names Ferré for board, raises $59m for ExAblate fibroid device | Medtech funding for the week of December 15, 2014

December 19, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: InSightec raises $59m, taps ex-Mako CEO Ferré for board; Engineer looks to crowdfund heart valve; Aethlon sells $3.3m in securities to investment fund; Stealthy Cotera raises nearly $8m for knee implants

InSightec raises $59m, taps ex-Mako CEO Ferré for board

December 15, 2014 by Brad Perriello

InSightec raises $59m, taps ex-Mako CEO Ferré for board

December 15, 2014 by Brad Perriello

InSightec says it raised $59 million for its ExAblate fibroid device and named ex-Mako Surgical CEO Dr. Maurice Ferré as chairman of the board.

InSightec raises $59m, taps ex-Mako CEO Ferré for board

InSightec said today that it reeled in a $59 million Series D round from institutional investors in the U.S. and Asia and named Dr. Maurice Ferré as chairman of the board.

InSightec developed the ExAblate MR-guided ultrasound targeting technology.

Medigus secures $5.6M in funding, reveals positive outcomes from study of its MUSE surgical endostapling device | Medtech funding for the week of September 15, 2014

September 19, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Medigus raises $5.6M, touts clinical results for acid reflux device; Funding: InSightec raises $12.5M from Chinese backers; Corindus raises $26.6M for vascular robot; Intrinsic Therapeutics raises $17.2M for spinal surgery devices

Medigus raises $5.6M, touts clinical results for acid reflux device

September 12, 2014 by Arezu Sarvestani

Medigus raises $5.6M, touts clinical results for acid reflux device

Funding: InSightec raises $12.5M from Chinese backers

September 16, 2014 by Arezu Sarvestani

A group of Chinese investors pays $12.5 million to acquire about 5% of Israeli ultrasound therapy devices maker InSightec.

Funding: Insightec raises $12.5M from Chinese backers

Israeli device maker InSightec added $12.5 million to its coffers thanks to the support of Chinese backers, the firm's parent company announced.

InSightec seeks $50M for ultrasound tumor therapy

June 30, 2014 by Arezu Sarvestani

InSightec launches a $50 million Series D funding round in support of its MR-guided ultrasound treatment, hoping to boost the round to $62.5 million.

InSightec seeks $50M for ultrasound tumor therapy

Israel-based InSightec is looking for a few investors to jump in on its $50 million Series D funding round, saying it'll use the funds to boost commercial efforts for its non-invasive tumor-targeting ultrasound therapy.

York Capital Management is already lined up to take a chunk out of the $50 million, leaving "limited time" for other prospective funders to jump in on the initial round or to expand fundraising to $62.5 million, InSightec said.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Canada green-lights InSightec's ablation system

August 22, 2013 by Sony Salzman

Canadian regulators give InSightec a nod of approval for the ExAblate system to treat benign uterine tumors and painful metastatic bone tumors.

Canada green-lights InSightec's ablation system

Canadian healthcare regulators approved InSightec's ExAblate ultrasound system, clearing the device for use against 2 different diseases. Health Canada granted ExAblate indication to break up benign uterine tumors and to alleviate painful symptoms of metastatic bone tumors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Insightec lands Chinese approval for ExAblate ultrasound tumor ablation

July 31, 2013 by Sony Salzman

Chinese regulators hand InSightec regulatory approval for the ExAblate ultrasound-based therapy to treat non-cancerous uterine tumors.

Insightec's ExAblate system

Israeli device maker InSightec landed a green light from the Chinese Food & Drug Administration for its ExAblate MRI-guided focused ultrasound therapy, with an indication to treat non-cancer-causing tumors in the uterus.

These tumors, called uterine fibroids, occur in more than 20% of women of childbearing age, according to the company. ExAblate is an incision-free treatment that uses ultrasound frequencies to ablate tumors.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp